PBAC's latest decision on Apomorphine: Recommended (2025). Considered for Treatment of Parkinson disease in patients with severely disabling motor fluctuations refractory to conventional therapy. Maintenance therapy in patients who have been commenced on treatment in a specialist unit in a hospital setting.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2016
Submissions
5
2016 → 2025
Eligible population
Patients with Parkinson disease who have experienced severely disabling motor fluctuations which have not responded to other therapy, and have been commenced on treatment in a specialist unit in a hospital setting.
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Apomine Solution for Infusion (apomorphine hydrochloride hemihydrate 100 mg/20 mL injection)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design
Submission history
Jul 2016: Recommended · Authority Required
Nov 2016: Recommended · Authority Required
Mar 2020: Recommended · Restricted
Nov 2020: Recommended with restriction · Authority Required